FDA Approves First-in-class Evkeeza (evinacumab-dgnb) for Young Children with Ultra-Rare Form of High Cholesterol

TARRYTOWN, N.Y., March 22, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has extended the approval of Evkeeza (evinacumab-dgnb) as an adjunct to other...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news